Skin melanoma. State of the problem. Review

Cover Page

Cite item

Full Text

Abstract

Skin melanoma, being the deadliest form of skin tumor, contributes significantly to cancer mortality and carries a significant and growing public health burden. The incidence of MK is growing steadily throughout the world and is in the nature of a “silent epidemic”. The critical mortality rate is due to the high metastatic potential of the tumor and the low efficiency of systemic therapy of disseminated forms of the disease. Thanks to a breakthrough in understanding the genetic mechanisms of the appearance of a tumor, the spread and tolerance to treatment, the emergence of a number of targeted and immunological drugs, patients with advanced MK have the hope of prolonging life and even complete cure. However, many diagnostic problems remain; treatment standards; emerging tolerance to therapy. All these questions compel further research into the diagnosis and treatment of this disease.

About the authors

S. A. Yargunin

Krasnodar cancer center #1

Author for correspondence.
Email: sdocer@rambler.ru

MD, PhD

Russian Federation, Krasnodar

A. F. Lazarev

Altay State Medical University

Email: sdocer@rambler.ru
Russian Federation, Barnaul

References

  1. Marzagalli M., Casati L., Moretti R.M., Montagnani M.M., Limonta P. Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS One. 2015; 10 (7): e0134396. doi: 10.1371/journal.pone.0134396. eCollection 2015. PMID: 26225426. PMCID: PMC4520550.
  2. Guy G.P., Machlin S.R., Ekwueme D.U., Yabroff K.R. Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011. Am. J. Prev. Med. 2015; 48: 183–187.
  3. Aliev M.D. Diagnosis and prognosis factors of skin melanoma. Sarkomy kostey, myagkih tkaney i opuholi kozhi. 2010; 1: 3–6. (In Russian)
  4. Salopek T.G., Jimbow K. Induction of melanogenesis during the various melanoma growth phases and the role of tyrosinase, lysosome-associated membrane proteins, and p90 calnexin in the melanogenesis cascade. J. Investig. Dermatol. Symp. Proc. 1996; 1(2):195–202. PMID: 9627716.
  5. Pellacani G., Pepe P., Casari A., Longo C. Reflectance confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: a longitudinal prospective study. Br. J. Dermatol. 2014; 171 (5): 1044–51. doi: 10.1111/bjd.13148. PMID: 24891083.
  6. Que S.K., Weston G., Suchecki J., Ricketts J. Pigmentary disorders of the eyes and skin. Clin. Dermatol. 2015; 33 (2): 147–58. doi: 10.1016/j.clindermatol.2014.10.007. Review. PMID: 25704935.
  7. Van der Ploeg A.P., van Akkooi A.C., Verhoef C., Eggermont A.M. Completion lymph node dissection after a positive sentinel node: no longer a must? Curr. Opin. Oncol. 2013; 25 (2): 152–9. doi: 10.1097/CCO.0b013e32835dafb4 .
  8. Solivetti F.M., Elia F., Graceffa D., Di Carlo A. Ultrasound morphology of inguinal lymph nodes may not herald an associated pathology. J. Exp. Clin. Cancer Res. 2012; 31 (1): 88 . doi: 10.1186/1756-9966-31-88. PMID: 23078807.
  9. Pasquali S., van der Ploeg A.P., Mocellin S., Stretch J.R., Thompson J.F., Scolyer R.A. Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. Pigment Cell Melanoma Res. 2013 May; 26 (3): 326–37. doi: 10.1111/pcmr.12064. PMID: 23298266.
  10. Morton D.L., Thompson J.F., Cochran A.J., Mozzillo N., Nieweg O.E., Roses D.F.; MSLT Group. Multicenter Selective Lymphadenectomy Trial. The New England J. of Medicine. 2014. 370 (7): 599–609. doi: 10.1056/NEJMoa1310460. PMID: 24521106. PMCID: PMC4058881.
  11. Bartolomei M., Testori A., Chinol M., Gennari R., De Cicco C., Leonardi L. et al.. Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping. Eur. J. Nucl. Med. 1998; 25 (11): 1489–94. doi: 10.1007/s002590050326. PMID: 9799344.
  12. Scolyer R.A., Judge M.J., Evans A., Frishberg D.P., Prieto V.G., Thompson J.F. et al. Data Set for Pathology Reporting of Cutaneous Invasive Melanoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Am. J. Surg. Pathol. 2013; 37 (12): 1797–1814. doi: 10.1097/PAS.0b013e31829d7f35. PMCID: PMC3864181.
  13. Thompson J.F, Scolyer R.A., Kefford R.F. Melanoma – a management guide for GPs. Aust. Fam. Physician. 2012; 41:470–473.
  14. Leong S.P.L., Mihm M.C., Jr., Murphy G.F., Hoon D.S.B., Kashani-Sabet M., Agarwala S.S. et al. Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis. 2012; 29 (7): 775–796. doi: 10.1007/s10585-012-9521-1. PMCID: PMC4311146.
  15. Agarwala S.S. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma. Expert Rev. Anticancer Ther. 2012; 12 (11): 1449–59. doi: 10.1586/era.12.120.
  16. Zitelli J.A., Brown C.D., Hanusa B.H. Surgical margins for excision of primary cutaneous melanoma. J. Am. Acad. Dermatol. 1997; 37 (3 Pt 1): 422–9. PMID: 9308558. doi: 10.1016/s0190-9622(97)70144-0.
  17. Nosrati A., Berliner J.G., Goel S., McGuire J., Morhenn V., de Souza J.R. et al. Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision. JAMA Dermatol. 2017; 153 (5): 436–41. doi: 10.1001/jamadermatol.2016.6138. PMID: 28241261.
  18. Thomas J.M., Newton-Bishop J., A’Hern R. et al. Excision margins in high-risk malignant melanoma. N. Engl. J. Med. 2004; 350: 757–66.
  19. Khayat D., Rixe O., Martin G., Soubrane C., Banzet M., Bazex J.A. et al.; French Group of Research on Malignant Melanoma. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003; 97 (8): 1941–6. PMID: 12673721. doi: 10.1002/cncr.11272.
  20. Demidov L.V., Utyashev I.A., Harkevich G.Y. The role of vemurafenib in the treatment of isseminated skin melanoma. Sovremennaya onkologiya. 2013; 2: 58–61. (In Russian)
  21. Pavri S.N., Clune J., Ariyan S., Narayan D. Malignant Melanoma: Beyond the Basics. Plast. Reconstr. Surg. 2016; 138 (2): 330e-40e. doi: 10.1097/PRS.0000000000002367. Review. PMID: 27465194.
  22. Khandelwal C.M., Meyers M.O., Yeh J.J., Amos K.D., Frank J.S., Long P., Ollila D.W. Relative value unit impact of complex skin closures to academic surgical melanomapractices. Am J Surg. 2012; 204 (3): 327–31. doi: 10.1016/j.amjsurg.2011.10.014. PMID: 22920403.
  23. Aglullin I.R., Safin I.R. Musculoskeletal plasty of skin and soft tissue defects in the treatment of malignant tumors. Sarkomy kostey, myagkih tkaney i opuholi kozhi. 2009; 1: 68–70. (In Russian)
  24. Batus M., Waheed S., Ruby C., Petersen L., Bines S.D., Kaufman H.L. Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions. Am. J. Clin. Dermatol. 2013; 14 (3): 179–194. doi: 10.1007/s40257-013-0025-9. PMCID: PMC3913474.
  25. Lee C.C., Faries M.B., Wanek L.A. et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J. Clin. Oncol. 2008; 26 (4): 535–541.
  26. Doussot A., Nardin C., Takaki H., Litchman T.D., D’Angelica M.I., Jarnagin W.R., Postow M.A., Erinjeri J.P., Kingham T.P. Liver resection and ablation for metastatic melanoma: A single center experience. J. Surg. Oncol. 2015; 111 (8): 962–8. doi: 10.1002/jso.23929. Epub 2015 Jun 12. PMID: 26073980.
  27. Caudle A.S., Ross M.I. Metastasectomy for stage IV melanoma: for whom and how much? Surg. Oncol. Clin. N. Am. 2011; 20 (1): 133–144.
  28. Hersh E.M., O’Day S.J., Ribas A. et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naïve patients with metastatic melanoma. Cancer. 2010; 116: 155–163.
  29. Albrecht K., Droll H., Giesler J.M., Nashan D., Meiss F., Reuter K. Self-efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression. Psychooncology. 2013 Jan 3. doi: 10.1002/pon.3238. PMID: 23288588.
  30. Ascierto P.A., Agarwala S.S., Botti G., Budillon A., Davies M.A. et al. Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy) J. Transl. Med. 2019; 17: 234. doi: 10.1186/s12967-019-1979-z. PMCID: PMC6647284.
  31. Harkevich G.Y., Orlova K.V., Demidov L.V. New drugs that restore immune control of the tumor in the treatment of patients with metastatic melanoma. Farmateka. 2014; 17: 25–30. (In Russian)
  32. Algazi A.P., Tsai K.T., Rosenblum M., Fox B.A., Andtbacka R.H.I., Li A. et al. Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12). J. Clin. Oncol. 2017; 35(suppl 7S; abstract 78).
  33. Atkins M.B., Gollob J.A., Sosman J.A. et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastin, temozolomide, interleukin 2, and IFN-α2B in patients with metastatic melanoma. Clin Cancer Res. 2002;8:3075–3081.
  34. Flaherty T.K. Targeting metastatic melanoma. Annu. Rev. Med. 2012; 63: 21.1–13.
  35. Fecher L.A., Cummings S.D., Keefe M.J., Alani R.M. Toward a molecular classification of melanoma. J. Clin. Oncol. 2007; 25 (12): 1606–20.
  36. Hauschild A., Grob J.J., Demidov L.V. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380 (9839): 358–365.
  37. Salama A.K., Hodi F.S. Cytotoxic T-lymphocyte-associated antigen-4. Clin. Cancer Res. 2011; 17:4622–4628.
  38. Nazarian R, Shi H., Wang Q. et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468: 973–7.
  39. Kirkwood J.M., Bastholt L., Robert C. et al. Phase II, open-label, randomized trial of the MEK 1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 2011; 18 (2): 555–67.
  40. Hodi F.S., Friedlander P., Corless C.L. et al. Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 2008; 26 (12): 2046–51.
  41. Curtin J.A., Busam K., Pinkel D. et al. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 2006; 24: 4340–6.
  42. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P, Larkin J. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011; 364 (26): 2507–16.
  43. Przhdeckij Y.V. Plastic repair of skin defects in cancer patients. Onkohirurgiya. Т.2, 2010: 17–23. (In Russian)
  44. Fedorenko I.V., Abel E.V., Koomen J.M., Fang B., Wood E.R., Chen Y.A. et al. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2016; 35(10): 1225–35 doi: 10.1038/onc.2015.188. PMID: 26073081.
  45. Ascierto P.A., Puzanov I., Agarwala S.S., Bifulco C., Botti G., Caracò C. et al. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy). J. Transl. Med. 2018; 16: 207. doi: 10.1186/s12967-018-1568-6. PMCID: PMC6054754.
  46. Amaria R.N., Reddy S.M., Tawbi H.A., Davies M.A., Ross M.I., Glitza I.C. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 2018; 24: 1649–1654. doi: 10.1038/s41591-018-0197-1.
  47. Amaria R.N., Prieto P.A., Tetzlaff M.T., Reuben A., Andrews M.C., Ross M.I. et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018; 19 (2):181–93. doi: 10.1016/S1470-2045(18)30015-9.
  48. Eggermont A.M.M., Blank C.U., Mandala M., Long G.V., Atkinson V., Dalle S. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 2018; 378(19):1789–1801. doi: 10.1056/NEJMoa1802357.
  49. Eggermont A.M., Chiarion-Sileni V., Grob J.J., Dummer R., Wolchok J.D., Schmidt H. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 2016; 375 (19): 1845–1855. doi: 10.1056/NEJMoa1611299.
  50. Tarhini A.A., Lee S.J., Li X., Rao U.N.M., Nagarajan A., Albertini M.R. et al. E3611—a randomized phase II study of ipilimumab at 3 or 10 mg/kg alone or in combination with high-dose interferon-α2b in advanced melanoma. Clin. Cancer Res. 2018. doi: 10.1158/1078-0432.ccr-18-2258.
  51. Weber J., Mandala M., Del Vecchio M., Gogas H.J., Arance A.M., Cowey C.L. et al. Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 2017;377(19):1824–1835. doi: 10.1056/NEJMoa1709030.
  52. Maio M., Lewis K., Demidov L., Mandalà M., Bondarenko I., Ascierto P.A.; BRIM8 Investigators. et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018; 19 (4): 510–520. doi: 10.1016/S1470-2045(18)30106-2.
  53. Long G.V., Hauschild A., Santinami M., Atkinson V., Mandalà M., Chiarion-Sileni V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 2017; 377:1813–1823. doi: 10.1056/NEJMoa1708539.
  54. Ascierto P.A., Dummer R. Immunological effects of BRAF + MEK inhibition. Oncoimmunology. 2018; 7 (9): e1468955. Doi: 10.1080 / 2162402X.2018.1468955.
  55. Long G.V., Atkinson V., Lo S., Sandhu S., Guminski A.D., Brown M.P. et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018; 19:672–681. doi: 10.1016/S1470-2045(18)30139-6.
  56. Faries M.B., Thompson J.F., Cochran A.J., Andtbacka R.H., Mozzillo N., Zager J.S. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N. Engl. J. Med. 2017; 376 (23): 2211–2222. doi: 10.1056/NEJMoa1613210.
  57. Douglas J.G., Margolin K. The treatment of brain metastases from malignant melanoma. Semin. Oncol. 2002; 29(5):518–524.
  58. Ewend M.G., Carey L.A., Brem H. Treatment of melanoma metastases in the brain. Semin. Surg. Oncol. 1996; 12 (6): 429–35. Review. PMID: 8914207. doi: 10.1002/(SICI)1098-2388(199611/12)12:6<429::AID-SSU8>3.0.CO;2-C.
  59. Davies M.A., Saiag P., Robert C., Grob J.J., Flaherty K.T., Arance A. et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18:863–873. doi: 10.1016/S1470-2045(17)30429-1.
  60. Tawbi H.A., Forsyth P.A., Algazi A., Hamid O., Hodi F.S., Moschos S.J. et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N. Engl. J. Med. 2018; 379:722–730. doi: 10.1056/NEJMoa1805453.
  61. Demaria S., Kawashima N., Yang A.M., Devitt M.L., Babb J.S., Allison J.P. et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 2005; 11(2 Pt 1): 728–734.
  62. Doss L.L., Memula N. The radioresponsiveness of melanoma. Int. J. Radiat. Oncol. Biol. Phys. 1982 Jul; 8(7):1131-4. PMID: 7118615. doi: 10.1016/0360-3016(82)90060-8.
  63. Farshad A., Burg G., Panizzon R., Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br. J. Dermatol. 2002; 146 (6): 1042–6. PMID: 12072074. doi: 10.1046/j.1365-2133.2002.04750.x.
  64. Arora A., Lowe L., Su L., Rees R., Bradford C., Cimmino V.C. et al. Wide excision without radiation for desmoplastic melanoma. Cancer. 2005; 104 (7): 1462–7. PMID: 16080180. doi: 10.1002/cncr.21311.
  65. Stevens G., Hong A. Radiation therapy in the management of cutaneous melanoma. Surg. Oncol. Clin. N. Am. 2006; 15(2): 353-71. Review. PMID: 16632220. doi: 10.1016/j.soc.2005.12.010.
  66. Seegenschmiedt M.H., Keilholz L., Altendorf-Hofmann A., Pieritz A., Urban A., Schell H. et al. [Long term results following radiation therapy of locally recurrent and metastatic malignant melanoma]. Hautarzt. 1999; 50(8): 572-9. German. PMID: 10460301. doi: 10.1007/s001050050961.
  67. Testori A., Rutkowski P., Marsden J., Bastholt L., Chiarion-Sileni V., Hauschild A., Eggermont A.M.M. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann. Oncol. 2009; 20 (Suppl 6): vi22–vi29. doi: 10.1093/annonc/mdp257. PMCID: PMC2712595.
  68. Eggermont A.M., de Wilt J.H., ten Hagen T.L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003; 4 (7):429–37. Review. PMID: 12850194. doi: 10.1016/s1470-2045(03)01141-0.
  69. Koops H.S., Vaglini M., Suciu S., Kroon B.B., Thompson J.F., Göhl J. et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J. Clin. Oncol. 1998 Sep; 16(9):2906-12. PMID: 9738557. doi: 10.1200/JCO.1998.16.9.2906.

Copyright (c) 2019 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies